{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T19:54:28Z","timestamp":1774468468253,"version":"3.50.1"},"reference-count":54,"publisher":"Pharmaceutical Society of Japan","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2021,8,1]]},"DOI":"10.1248\/bpb.b21-00363","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T22:07:32Z","timestamp":1627769252000},"page":"1140-1150","source":"Crossref","is-referenced-by-count":4,"title":["Inhibitory Effects of Antipsychotics on the Contractile Response to Acetylcholine in Rat Urinary Bladder Smooth Muscles"],"prefix":"10.1248","volume":"44","author":[{"given":"Keisuke","family":"Obara","sequence":"first","affiliation":[{"name":"Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Toho University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Toho University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Toho University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukako","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Toho University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Ikegami","sequence":"additional","affiliation":[{"name":"Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Toho University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanako","family":"Shioda","sequence":"additional","affiliation":[{"name":"Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Toho University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yume","family":"Hattori","sequence":"additional","affiliation":[{"name":"Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Toho University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Hamamatsu","sequence":"additional","affiliation":[{"name":"Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Toho University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kento","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Toho University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiko","family":"Yamaki","sequence":"additional","affiliation":[{"name":"Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Toho University"},{"name":"Department of Pharmacy, Faculty of Pharmacy, Musashino University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yoshio","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Toho University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Bosnjak SM, Dimitrijevic J, Djordjevic F. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine. <i>Curr. Opin. Support. Palliat. Care<\/i>, <b>10<\/b>, 180\u2013188 (2016).","DOI":"10.1097\/SPC.0000000000000206"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Chiesa D, Marengoni A, Nobili A, Tettamanti M, Pasina L, Franchi C, Djade CD, Corrao S, Salerno F, Marcucci M, Romanelli G, Mannucci PM. Antipsychotic prescription and mortality in hospitalized older persons. <i>Psychogeriatrics<\/i>, <b>17<\/b>, 397\u2013405 (2017).","DOI":"10.1111\/psyg.12263"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. <i>Br. Med. Bull.<\/i>, <b>114<\/b>, 169\u2013179 (2015).","DOI":"10.1093\/bmb\/ldv017"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Trifir\u00f3 G, Sultana J, Spina E. Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies. <i>Drug Saf.<\/i>, <b>37<\/b>, 501\u2013520 (2014).","DOI":"10.1007\/s40264-014-0170-y"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Zhou X, Keitner GI, Qin B, Ravindran AV, Bauer M, Del Giovane C, Zhao J, Liu Y, Fang Y, Zhang Y, Xie P. Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis. <i>Int. J. Neuropsychopharmacol.<\/i>, <b>18<\/b>, pyv060 (2015).","DOI":"10.1093\/ijnp\/pyv060"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Kochi K, Sato I, Nishiyama C, Tanaka-Mizuno S, Doi Y, Arai M, Fujii Y, Matsunaga T, Ogawa Y, Furukawa TA, Kawakami K. Trends in antipsychotic prescriptions for Japanese outpatients during 2006\u20132012: a descriptive epidemiological study. <i>Pharmacoepidemiol. Drug Saf.<\/i>, <b>26<\/b>, 642\u2013656 (2017).","DOI":"10.1002\/pds.4187"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) H\u00e1lfd\u00e1narson O, Zo\u00ebga H, Aagaard L, <i>et al.<\/i> International trends in antipsychotic use: A study in 16 countries, 2005\u20132014. <i>Eur. Neuropsychopharmacol.<\/i>, <b>27<\/b>, 1064\u20131076 (2017).","DOI":"10.1016\/j.euroneuro.2017.07.001"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Raschi E, Poluzzi E, Godman B, Koci A, Moretti U, Kalaba M, Bennie M, Barbui C, Wettermark B, Sturkenboom M, De Ponti F. Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. <i>PLOS ONE<\/i>, <b>8<\/b>, e81208 (2013).","DOI":"10.1371\/journal.pone.0081208"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Deak F, Freeman WM, Ungvari Z, Csiszar A, Sonntag WE. Recent developments in understanding brain aging: implications for Alzheimer\u2019s disease and vascular cognitive impairment. <i>J. Gerontol. A Biol. Sci. Med. Sci.<\/i>, <b>71<\/b>, 13\u201320 (2016).","DOI":"10.1093\/gerona\/glv206"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Kudryavtseva AV, Krasnov GS, Dmitriev AA, Alekseev BY, Kardymon OL, Sadritdinova AF, Fedorova MS, Pokrovsky AV, Melnikova NV, Kaprin AD, Moskalev AA, Snezhkina AV. Mitochondrial dysfunction and oxidative stress in aging and cancer. <i>Oncotarget<\/i>, <b>7<\/b>, 44879\u201344905 (2016).","DOI":"10.18632\/oncotarget.9821"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Karel MJ, Gatz M, Smyer MA. Aging and mental health in the decade ahead: what psychologists need to know. <i>Am. Psychol.<\/i>, <b>67<\/b>, 184\u2013198 (2012).","DOI":"10.1037\/a0025393"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. <i>Drugs Aging<\/i>, <b>17<\/b>, 363\u2013384 (2000).","DOI":"10.2165\/00002512-200017050-00004"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Gareri P, Segura-Garcia C, Manfredi VG, Bruni A, Ciambrone P, Cerminara G, De Sarro G, De Fazio P. Use of atypical antipsychotics in the elderly: a clinical review. <i>Clin. Interv. Aging<\/i>, <b>9<\/b>, 1363\u20131373 (2014).","DOI":"10.2147\/CIA.S63942"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. <i>Arch. Intern. Med.<\/i>, <b>170<\/b>, 96\u2013103 (2010).","DOI":"10.1001\/archinternmed.2009.456"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Ozbilen M, Adams CE, Marley J. Anticholinergic effects of oral antipsychotic drugs of typicals <i>versus<\/i> atypicals over medium- and long-term: systematic review and meta-analysis. <i>Curr. Med. Chem.<\/i>, <b>19<\/b>, 5214\u20135218 (2012).","DOI":"10.2174\/092986712803530476"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Verhamme KMC, Sturkenboom MCJM, Stricker BHC, Bosch R. Drug-induced urinary retention: incidence, management and prevention. <i>Drug Saf.<\/i>, <b>31<\/b>, 373\u2013388 (2008).","DOI":"10.2165\/00002018-200831050-00002"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Uher R, Farmer A, Henigsberg N, <i>et al.<\/i> Adverse reactions to antidepressants. <i>Br. J. Psychiatry<\/i>, <b>195<\/b>, 202\u2013210 (2009).","DOI":"10.1192\/bjp.bp.108.061960"},{"key":"18","unstructured":"18) Obara K, Chino D, Tanaka Y. The recovery effects of distigmine on guinea pig detrusor underactivity induced by anticholinergic drugs. <i>\u014cy\u014d Yakuri\/Pharmacometrics<\/i>, <b>91<\/b>, 25\u201339 (2016)."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Anisuzzaman AS, Morishima S, Suzuki F, Tanaka T, Yoshiki H, Sathi ZS, Akino H, Yokoyama O, Muramatsu I. Assessment of muscarinic receptor subtypes in human and rat lower urinary tract by tissue segment binding assay. <i>J. Pharmacol. Sci.<\/i>, <b>106<\/b>, 271\u2013279 (2008).","DOI":"10.1254\/jphs.FP0071435"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Palea S, Rekik M, Rouget C, Camparo P, Botto H, Rischmann P, Lluel P, Westfall TD. Fenoterol functionally activates the \u03b2<sub>3<\/sub>-adrenoceptor in human urinary bladder, comparison with rat and mouse: implications for drug discovery. <i>Eur. J. Pharmacol.<\/i>, <b>690<\/b>, 202\u2013206 (2012).","DOI":"10.1016\/j.ejphar.2012.06.036"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Obara K, Ao L, Ogawa T, Ikarashi T, Yamaki F, Matsuo K, Yoshio T, Tanaka Y. Assessment of inhibitory effects of hypnotics on acetylcholine-induced contractions in isolated rat urinary bladder smooth muscle. <i>Biol. Pharm. Bull.<\/i>, <b>42<\/b>, 280\u2013288 (2019).","DOI":"10.1248\/bpb.b18-00829"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Obara K, Ao L, Shimada T, Horiguchi S, Ikarashi T, Ogawa T, Yoshioka K, Yamaki F, Matsuo K, Yoshio T, Tanaka Y. Pharmacological characteristics of anxiolytics on acetylcholine-induced contractions in rat detrusor smooth muscle. <i>Pharmacology<\/i>, <b>105<\/b>, 369\u2013376 (2020).","DOI":"10.1159\/000503885"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Obara K, Horiguchi S, Shimada T, Ikarashi T, Yamaki F, Matsuo K, Yoshio T, Tanaka Y. Characterization of binding of antipsychotics to muscarinic receptors using mouse cerebral cortex. <i>J. Pharmacol. Sci.<\/i>, <b>140<\/b>, 197\u2013200 (2019).","DOI":"10.1016\/j.jphs.2019.05.006"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT. Radioreceptor binding profile of the atypical antipsychotic olanzapine. <i>Neuropsychopharmacology<\/i>, <b>14<\/b>, 87\u201396 (1996).","DOI":"10.1016\/0893-133X(94)00129-N"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Bymaster FP, Felder CC, Tzavara E, Nomikos GG, Calligaro DO, McKinzie DL. Muscarinic mechanisms of antipsychotic atypicality. <i>Prog. Neuropsychopharmacol. Biol. Psychiatry<\/i>, <b>27<\/b>, 1125\u20131143 (2003).","DOI":"10.1016\/j.pnpbp.2003.09.008"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Frazier EP, Peters SLM, Braverman AS, Ruggieri MR Sr, Michel MC. Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors. <i>Naunyn Schmiedebergs Arch. Pharmacol.<\/i>, <b>377<\/b>, 449\u2013462 (2008).","DOI":"10.1007\/s00210-007-0208-0"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Hals PA, Hall H, Dahl SG. Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. <i>Life Sci.<\/i>, <b>43<\/b>, 405\u2013412 (1988).","DOI":"10.1016\/0024-3205(88)90519-X"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. <i>Life Sci.<\/i>, <b>68<\/b>, 29\u201339 (2000).","DOI":"10.1016\/S0024-3205(00)00911-5"},{"key":"29","unstructured":"29) Sah DW, Bean BP. Inhibition of P-type and N-type calcium channels by dopamine receptor antagonists. <i>Mol. Pharmacol.<\/i>, <b>45<\/b>, 84\u201392 (1994)."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Ito K, Nakazawa K, Koizumi S, Liu M, Takeuchi K, Hashimoto T, Ohno Y, Inoue K. Inhibition by antipsychotic drugs of L-type Ca<sup>2+<\/sup> channel current in PC12 cells. <i>Eur. J. Pharmacol.<\/i>, <b>314<\/b>, 143\u2013150 (1996).","DOI":"10.1016\/S0014-2999(96)00500-6"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Kamei A, Mizumoto Y, Takehana M. The relationship between properties of antipsychotic drugs and cataract formation. <i>Biol. Pharm. Bull.<\/i>, <b>17<\/b>, 237\u2013242 (1994).","DOI":"10.1248\/bpb.17.237"},{"key":"32","unstructured":"32) Prokopenko RA, Mogilevich SE, Luik AI, Naydyenova IY, Batrak GN, Hawryluk BR, Degtiar VY. Effects of haloperidol and chlorpromazine on smooth muscle contractility, platelet aggregation and neuronal calcium current. <i>Gen. Physiol. Biophys.<\/i>, <b>14<\/b>, 349\u2013357 (1995)."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Maruoka Y, Ohno Y, Kato T, Hirose A, Tatsuno T, Nakamura M. Effects of SM-9018, a potential atypical neuroleptic, on the central monoaminergic system in rats. <i>Jpn. J. Pharmacol.<\/i>, <b>62<\/b>, 419\u2013422 (1993).","DOI":"10.1254\/jjp.61.283"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Shahid M, Walker GB, Zorn SH, Wong EHF. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. <i>J. Psychopharmacol.<\/i>, <b>23<\/b>, 65\u201373 (2009).","DOI":"10.1177\/0269881107082944"},{"key":"35","unstructured":"35) A Product monograph for Saphris<sup>\u00ae<\/sup> tablets provided by Merck Canada Inc. (Kirkland, QC, Canada)."},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Uno J, Obara K, Suzuki H, Miyatani S, Chino D, Yoshio T, Tanaka Y. Inhibitory effects of antidepressants on acetylcholineinduced contractions in isolated guinea pig urinary bladder smooth muscle. <i>Pharmacology<\/i>, <b>99<\/b>, 89\u201398 (2017).","DOI":"10.1159\/000452221"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Winek CL, Wahba WW, Winek CL Jr, Balzer TW. Drug and chemical blood-level data 2001. <i>Forensic Sci. Int.<\/i>, <b>122<\/b>, 107\u2013123 (2001).","DOI":"10.1016\/S0379-0738(01)00483-2"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Tashiro M, Naito T, Kagawa Y, Kawakami J. Simultaneous determination of prochlorperazine and its metabolites in human plasma using isocratic liquid chromatography tandem mass spectrometry. <i>Biomed. Chromatogr.<\/i>, <b>26<\/b>, 754\u2013760 (2012).","DOI":"10.1002\/bmc.1725"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Someya T, Muratake T, Hirokane G, Shibasaki M, Shimoda K, Takahashi S. Interindividual variation in bromperidol metabolism and relationship to therapeutic effects. <i>J. Clin. Psychopharmacol.<\/i>, <b>20<\/b>, 175\u2013180 (2000).","DOI":"10.1097\/00004714-200004000-00009"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Shimoda K, Someya T, Morita S, Hirokane G, Yokono A, Shibasaki M, Takahashi S. Plasma concentrations of timiperone and its reduced metabolite in the patients on timiperone. <i>Psychiatry Clin. Neurosci.<\/i>, <b>52<\/b>, 535\u2013540 (1998).","DOI":"10.1046\/j.1440-1819.1998.00421.x"},{"key":"41","unstructured":"41) An interview form for Spiropitan<sup>\u00ae<\/sup> tablets was provided by Eisai Co., Ltd. (Tokyo, Japan)."},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Potgieter GE, Groenewoud G, Jordaan PJ, Hundt HK, Schall R, Kummer M, Sewarte-Ross G. Pharmacokinetics of pipamperone from three different tablet formulations. <i>Arzneimittelforschung<\/i>, <b>52<\/b>, 430\u2013434 (2002).","DOI":"10.1055\/s-0031-1299910"},{"key":"43","unstructured":"43) Tokunaga H, Kudo K, Imamura T, Jitsufuchi N, Ohtsuka Y, Ikeda N. Plasma concentrations of antipsychotic drugs in psychiatric inpatients. <i>Nihon Hoigaku Zasshi<\/i>, <b>51<\/b>, 417\u2013422 (1997)."},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Roos RA, de Haas EJ, Buruma OJ, de Wolff FA. Pharmacokinetics of tiapride in patients with tardive dyskinesia and Huntington\u2019s disease. <i>Eur. J. Clin. Pharmacol.<\/i>, <b>31<\/b>, 191\u2013194 (1986).","DOI":"10.1007\/BF00606657"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Mihara K, Kondo T, Suzuki A, Yasui N, Nagashima U, Ono S, Otani K, Kaneko S. Prolactin response to nemonapride, a selective antagonist for D<sub>2<\/sub> like dopamine receptors, in schizophrenic patients in relation to <i>Taq<\/i>1A polymorphism of <i>DRD2<\/i> gene. <i>Psychopharmacology<\/i>, <b>149<\/b>, 246\u2013250 (2000).","DOI":"10.1007\/s002139900364"},{"key":"46","unstructured":"46) Noda K, Suzuki A, Okui M, Noguchi H, Nishiura N, Nishiura N. Pharmacokinetics and metabolism of 2-chloro-11-(2-dimethylaminoethoxy)-dibenzo[<i>b<\/i>,<i>f<\/i>]thiepine (zotepine) in rat, mouse, dog and man. <i>Arzneimittelforschung<\/i>, <b>29<\/b>, 1595\u20131600 (1979)."},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) van der Weide K, van der Weide J. The influence of the <i>CYP3A4*22<\/i> polymorphism and <i>CYP2D6<\/i> polymorphisms on serum concentrations of aripiprazole, haloperidol, pimozide, and risperidone in psychiatric patients. <i>J. Clin. Psychopharmacol.<\/i>, <b>35<\/b>, 228\u2013236 (2015).","DOI":"10.1097\/JCP.0000000000000319"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Wang ST, Li Y. Development of a UPLC-MS\/MS method for routine therapeutic drug monitoring of aripiprazole, amisulpride, olanzapine, paliperidone and ziprasidone with a discussion of their therapeutic reference ranges for Chinese patients. <i>Biomed. Chromatogr.<\/i>, <b>31<\/b>, e3928 (2017).","DOI":"10.1002\/bmc.3928"},{"key":"49","unstructured":"49) Gen K, Morokawa Y, Inoue Y, Miyake N, Sekiguchi G, Akomoto T, Suzuki H, Ishizeki K, Takagi H, Tanaka A, Aoba A. Daily dosage of Perospirone, concentrations of nonmetabolized drug and metabolite ID-15036 in plasma, and anti-dopamine (D<sub>2<\/sub>) and anti-serotonin (5-HT<sub>2A<\/sub>) activities in plasma. <i>Jpn. J. Clin. Psychopharmacol.<\/i>, <b>9<\/b>, 1581\u20131589 (2006)."},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Suzuki H, Gen K. The relationship between the daily dose, the plasma concentration of blonanserin, and its plasma anti-dopamine D<sub>2<\/sub> and anti-serotonin 5-HT<sub>2A<\/sub> activity. <i>Hum. Psychopharmacol.<\/i>, <b>25<\/b>, 342\u2013346 (2010).","DOI":"10.1002\/hup.1124"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Ishigooka J, Iwashita S, Higashi K, Liew EL, Tadori Y. Pharmacokinetics and safety of brexpiprazole following multiple-dose administration to Japanese patients with schizophrenia. <i>J. Clin. Pharmacol.<\/i>, <b>58<\/b>, 74\u201380 (2018).","DOI":"10.1002\/jcph.979"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) van der Weide K, van der Weide J. The influence of the <i>CYP3A4*22<\/i> polymorphism on serum concentration of quetiapine in psychiatric patients. <i>J. Clin. Psychopharmacol.<\/i>, <b>34<\/b>, 256\u2013260 (2014).","DOI":"10.1097\/JCP.0000000000000070"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Rajji TK, Mulsant BH, Davies S, Kalache SM, Tsoutsoulas C, Pollock BG, Remington G. Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to <i>N<\/i>-desmethylclozapine. <i>Am. J. Psychiatry<\/i>, <b>172<\/b>, 579\u2013585 (2015).","DOI":"10.1176\/appi.ajp.2015.14050673"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Dogterom P, Timmer C, de Greef R, Spaans E, de Vries D, van Vliet A, Peeters P. Asenapine safety, tolerability, and pharmacokinetics after single and multiple doses in healthy volunteers. <i>Clin. Pharmacol. Drug Dev.<\/i>, <b>1<\/b>, 131\u2013143 (2012).","DOI":"10.1177\/2160763X12455328"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/8\/44_b21-00363\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T04:36:51Z","timestamp":1715143011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/8\/44_b21-00363\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,1]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b21-00363","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,1]]},"article-number":"b21-00363"}}